ERBB2 and breast carcinoma: On the contrary, the significantly higher proportion of breast cancer patients in the control group associates with a more frequent application of trastuzumab being applied as an adjuvant treatment of human epidermal growth factor receptor (Her2)-overexpressing breast cancer [52].